In June 2010, the drug company Novo Nordisk announced that its only conventional human biphasic insulin, human Mixtard 30, would no longer be available in the UK from January 2011, a decision that affects an estimated 90,000 patients. The alternative biphasic analogue insulins are more expensive than Mixtard 30. Assuming a direct swap to Novo Nordisk's analogue biphasic insulin, NovoMix 30, the increased prescribing costs could be over …